You can buy or sell GNMX and other stocks, options, ETFs, and crypto commission-free!
Aevi Genomic Medicine, Inc. Common Stock, also called Aevi Genomic Medicine, is a clinical stage biopharmaceutical company, which engages in finding treatments for rare and orphan diseases. Read More Its research and development efforts leverage an internal genomics platform and an ongoing collaboration with the Center for Applied Genomics (CAG) at The Children's Hospital of Philadelphia (CHOP). The company was founded on January 27, 2000 and is headquartered in Wayne, PA.
52 Week High
52 Week Low
Research And Development
Stock Price, News, & Analysis for Aevi Genomic Medicine
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imb...
-$0.16 per share
Expected Today, Pre-Market